Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 08, 2023

SELL
$21.53 - $26.8 $2,669 - $3,323
-124 Reduced 0.4%
31,060 $719,000
Q4 2022

Feb 14, 2023

SELL
$18.63 - $27.35 $7,694 - $11,295
-413 Reduced 1.31%
31,184 $817,000
Q3 2022

Nov 10, 2022

BUY
$17.51 - $23.37 $717 - $958
41 Added 0.13%
31,597 $621,000
Q2 2022

Aug 12, 2022

BUY
$12.59 - $18.8 $397,290 - $593,252
31,556 New
31,556 $552,000
Q1 2022

May 04, 2022

SELL
$12.02 - $16.69 $632,937 - $878,845
-52,657 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$10.69 - $16.83 $9,621 - $15,146
-900 Reduced 1.68%
52,657 $859,000
Q3 2021

Nov 08, 2021

SELL
$11.5 - $14.86 $3,450 - $4,458
-300 Reduced 0.56%
53,557 $684,000
Q2 2021

Aug 09, 2021

BUY
$13.6 - $18.98 $732,455 - $1.02 Million
53,857 New
53,857 $761,000

Others Institutions Holding KDNY

About CHINOOK THERAPEUTICS, INC.


  • Ticker KDNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,896,300
  • Description
  • Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...
More about KDNY
Track This Portfolio

Track Clari Vest Asset Management LLC Portfolio

Follow Clari Vest Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Clari Vest Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Clari Vest Asset Management LLC with notifications on news.